Almac Group Launches claraT – A Unique, Software-driven Gene Expression Report

Bioinformatics

Almac Diagnostic Services has launched claraT – a unique software-driven solution, classifying biologically relevant gene expression signatures into a comprehensive, easy-to-interpret report.

The claraT report will benefit BioPharma and Academic biomarker discovery and translational research. Clients are provided with an interactive report that allows the easy visualisation of the key discriminating biologies within both the study cohort and an individual tumour sample.

claraT classifies relevant published gene expression signatures, alongside Almac’s own proprietary assays and single gene targets linked to multiple key biologies, according to the well-established 10 Hallmarks of Cancer. The claraT report is a pan-cancer solution generated from raw gene expression data, utilising Almac’s RNA-Sequencing Service.

RNA-Sequencing data is extremely complex and difficult to interpret, often requiring extensive bioinformatics expertise. Almac has developed proprietary bioinformatics pipelines to report this complex data through claraT in a simplified manner, helping to save time and maximise the understanding of any dataset more quickly.

The claraT report classifies using the Hallmarks of Cancer for easy interpretation. Initial launch content includes 35 gene expression signatures and 30 single gene drug targets (in addition to other biology linked genes). The first three featured hallmark biologies included are: immuno-oncology (IO), epithelial to mesenchymal transition (EMT) and angiogenesis. Almac will continue to expand the claraTreport by developing content to ultimately cover all 10 Hallmarks of Cancer.

Michael Sloan, Global VP of Commercial Operations, Almac Diagnostic Services stated:

RNA-Sequencing produces vast amounts of complex raw data that can be difficult to interpret. We believe claraT offers a unique and highly cost-effective solution to this problem for BioPharma clients. From a single tumour sample sent to Almac’s labs, claraT provides multiple biologically relevant signature readouts in an easy to interpret report, saving time and allowing researchers to identify key patterns of gene expression within their cohort.

“claraT further enhances Almac Diagnostic Services’ capabilities within RNA expression profiling. The value of RNA alongside DNA in stratified medicine is slowly starting to be realised and Almac are hoping to provide further proof of its importance with our claraT gene expression report.

We are excited by the potential effect claraT may have for future oncology biomarker discovery research.”

For further information on claraT visit the www.almacgroup.com/diagnostics/claratreport

To book a meeting with Almac to discuss claraT at ESMO 2018.

Source – Almac Diagnostics

Articles You May Like

The lung microenvironment: an important regulator of tumour growth and metastasis
Russian cosmonauts take spacewalk to probe mystery of craft hole
Get ready! Here’s what you can expect from this week’s Geminids meteor shower
The legacy of human civilisation will be written in chicken bones
CDC: Raw Cookie Dough? Why You Should Just Say No

Leave a Reply

Your email address will not be published. Required fields are marked *